Fortitude Biomedicines launched with $13 million in seed funding to develop antibody‑drug conjugates carrying targeted protein degraders (GLUE‑DAC), aiming to overcome ADC resistance and expand ADC utility into autoimmune disease. Founders include academic leaders from Baylor College of Medicine and serial entrepreneurs; K2 Bio Partners and Shanghai Healthcare Angel Capital led the round. The startup will use a discovery engine to attach molecular glue degraders as ADC payloads, seeking catalytic degradation inside targeted cells rather than traditional cytotoxic payloads. Fortitude positions GLUE‑DAC as a strategy to broaden ADC targets and address resistance mechanisms that limit current ADC durability.